Scandion Oncology Feed

	Tid*
2025-11-11	07:00	Kvartalsrapport 2025-Q3
2025-08-28	07:00	Kvartalsrapport 2025-Q2
2025-05-22	07:00	Kvartalsrapport 2025-Q1
2025-04-29	N/A	Årsstämma
2025-02-27	07:00	Bokslutskommuniké 2024
2024-11-11	-	Kvartalsrapport 2024-Q3
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-04-25	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2024-04-24	-	Årsstämma
2024-02-28	-	Bokslutskommuniké 2023
2023-11-22	-	Kvartalsrapport 2023-Q3
2023-08-23	-	Kvartalsrapport 2023-Q2
2023-05-26	-	Kvartalsrapport 2023-Q1
2023-04-27	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2023-04-26	-	Årsstämma
2023-02-22	-	Bokslutskommuniké 2022
2022-11-16	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-19	-	Kvartalsrapport 2022-Q1
2022-04-28	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2022-04-27	-	Årsstämma
2022-02-17	-	Bokslutskommuniké 2021
2021-11-18	-	Kvartalsrapport 2021-Q3
2021-11-17	-	Extra Bolagsstämma 2021
2021-08-19	-	Kvartalsrapport 2021-Q2
2021-05-27	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2021-05-26	-	Årsstämma
2021-05-20	-	Kvartalsrapport 2021-Q1
2021-02-18	-	Bokslutskommuniké 2020
2020-11-19	-	Kvartalsrapport 2020-Q3
2020-08-20	-	Kvartalsrapport 2020-Q2
2020-05-28	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2020-05-27	-	Årsstämma
2020-05-21	-	Kvartalsrapport 2020-Q1
2020-02-20	-	Bokslutskommuniké 2019
2019-11-21	-	Kvartalsrapport 2019-Q3
2019-08-22	-	Kvartalsrapport 2019-Q2
2019-06-11	-	Extra Bolagsstämma 2019
2019-05-31	-	X-dag ordinarie utdelning SCOL 0.00 SEK
2019-05-29	-	Årsstämma
2019-05-27	-	Kvartalsrapport 2019-Q1
2019-02-21	-	Bokslutskommuniké 2018
2018-11-18	-	Kvartalsrapport 2018-Q3

Land	Danmark
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2024-11-20 17:30:00 Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 0,08 SEK | -1,95% | 0,04 MSEK

2024-11-14 08:30:00 Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024 0,08 SEK | +14,79% | 0,08 MSEK

2024-11-11 07:00:00 Scandion Oncology – Interim Report Q3 2024 0,07 SEK | -4,83% | 0,29 MSEK

2024-11-05 17:00:00 Invitation to Scandion Oncology webcast and conference call November 11, 2024 0,09 SEK | 0,00% | 0,06 MSEK

2024-11-04 08:30:00 Scandion Oncology announces the start of the exercise period for warrants of series TO 2 0,09 SEK | -13,00% | 0,19 MSEK

2024-10-31 08:30:00 Correction: Scandion Oncology announces exercise price for warrants of series TO 2 0,12 SEK | -2,48% | 0,05 MSEK

2024-10-30 17:00:00 Scandion Oncology announces exercise price for warrants of series TO 2 0,12 SEK | +1,68% | 0,02 MSEK

2024-08-29 07:00:00 Scandion Oncology – Interim Report Q2 2024 0,16 SEK | +3,23% | 0,15 MSEK

2024-08-19 07:00:00 Scandion Oncology strengthens partnering outreach 0,18 SEK | +13,29% | 0,24 MSEK

2024-08-16 07:00:00 Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3 0,16 SEK | -1,86% | 0,09 MSEK

2024-07-11 08:00:00 SCANDION ONCOLOGY'S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY 0,21 SEK | +0,96% | 0,05 MSEK

2024-07-01 17:30:00 Scandion Oncology board member Michel Ducreux steps down, joins advisory board 0,26 SEK | -10,34% | 0,07 MSEK

2024-06-25 17:30:00 SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 0,29 SEK | -24,08% | 0,27 MSEK

2024-06-03 17:00:00 Scandion announces change of Certified Adviser to Vator Securities 0,65 SEK | +8,33% | 0,13 MSEK

2024-05-31 12:00:00 SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE 0,60 SEK | +182,67% | 0,19 MSEK

2024-05-23 22:30:00 SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 0,27 SEK | -25,21% | 0,93 MSEK

2024-05-22 07:00:00 Scandion Oncology – Interim Report Q1 2024 0,38 SEK | +4,64% | 0,27 MSEK

2024-05-16 17:00:00 Invitation to Scandion Oncology webcast and conference call May 22, 2024 0,41 SEK | +0,37% | 0,02 MSEK

2024-05-13 07:00:00 Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 0,42 SEK | +2,58% | 0,19 MSEK

2024-05-06 16:30:00 Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors 0,40 SEK | +0,76% | 0,08 MSEK

2024-05-03 08:00:00 Scandion Oncology to Host R&D Update May 15 0,40 SEK | +1,16% | 0,05 MSEK

2024-04-19 08:30:00 Scandion Oncology – Notice convening the Annual General Meeting 0,49 SEK | -35,48% | 1,98 MSEK

2024-04-19 08:00:00 SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION 0,49 SEK | -35,48% | 1,98 MSEK

2024-03-21 07:00:00 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival 0,58 SEK | +5,44% | 0,23 MSEK

2024-03-15 07:00:00 Scandion Oncology - Annual Report 2023 0,65 SEK | +1,90% | 0,06 MSEK

2024-03-07 07:00:00 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial 0,67 SEK | +2,81% | 0,41 MSEK

2024-02-28 07:00:00 Scandion Oncology – Q4 & yearend report 2023 0,69 SEK | -8,65% | 0,16 MSEK

2024-02-22 16:00:00 Invitation to Scandion Oncology webcast and conference call February 28, 2024 0,85 SEK | +13,85% | 0,37 MSEK

2024-01-31 07:00:00 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial 1,19 SEK | +3,97% | 9,49 MSEK

2024-01-05 08:30:00 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 1,29 SEK | +12,25% | 0,89 MSEK

2023-12-21 17:30:00 CORIST part 3 topline data are expected in the second half of January 2024 1,30 SEK | +14,25% | 6,65 MSEK

2023-12-15 08:30:00 Scandion Oncology identifies potentially effective treatment of gastric cancer 0,61 SEK | +22,28% | 1,91 MSEK

2023-11-29 08:30:00 Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 0,58 SEK | +7,96% | 0,28 MSEK

2023-11-22 08:30:00 Scandion Oncology – Interim Report Q3 2023 0,52 SEK | -2,30% | 0,90 MSEK

2023-11-21 08:30:00 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months 0,53 SEK | +45,73% | 1,99 MSEK

2023-11-15 16:00:00 Invitation to Scandion Oncology webcast and conference call November 22, 2023 0,37 SEK | -3,89% | 0,06 MSEK

2023-10-16 00:05:00 Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data. 1,42 SEK | -1,53%

2023-09-12 07:00:00 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer 0,48 SEK | +1,66% | 0,05 MSEK

2023-08-23 08:30:00 Scandion Oncology – Interim Report Q2 2023 0,53 SEK | +2,11% | 0,10 MSEK

2023-08-17 08:30:00 Data from PANTAX trial to be presented at ESMO Congress 2023 0,48 SEK | -1,13% | 0,08 MSEK

2023-08-16 08:30:00 Invitation to Scandion Oncology webcast and conference call August 23, 2023 0,48 SEK | +3,23% | 0,07 MSEK

2023-07-18 07:00:00 The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101 0,53 SEK | +8,90% | 0,07 MSEK

2023-05-26 08:30:00 Scandion Oncology – Interim Report Q1 2023 0,47 SEK | -1,66% | 0,14 MSEK

2023-05-19 08:30:00 Invitation to Scandion Oncology webcast and conference call May 26, 2023 0,48 SEK | -3,09% | 0,06 MSEK

2023-04-26 17:30:00 Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors 0,53 SEK | -2,54% | 0,06 MSEK

2023-04-11 08:30:00 Scandion Oncology – Notice convening the Annual General Meeting 0,53 SEK | -6,91% | 0,33 MSEK

2023-03-31 10:00:00 Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) 0,65 SEK | -1,39% | 0,71 MSEK

2023-03-28 08:30:00 Scandion Oncology - Annual Report 2022 0,61 SEK | -11,89% | 0,19 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Scandion Oncology

Prenumeration

Kalender

Beskrivning

Scandion Oncology

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden